Use of natural killer (NK) cells carrying an anti-spike mAb as covid19 therapy
- Funded by ANR
- Total publications:244 publications
Grant number: Unknown
Grant search
Key facts
Disease
COVID-19Funder
ANRPrincipal Investigator
. Martin VILLALBAResearch Location
FranceLead Research Institution
CHRU de MontpellierResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The CoviNK project, coordinated by Martin Villalba (UMR U1183 Institute of Regenerative Medicine and Biotherapies (IMRB) - CHRU de Montpellier), proposes to use natural killer cells (NK) carrying an anti-spike mAb, for the treatment of COVID -19. The team will be based on an expanded NK (eNK) production protocol patented by Inserm, and on a new approach for stably loading monoclonal antibodies (mAbs) on the membrane of NK cells, currently being developed for the cancer therapy.
Publicationslinked via Europe PMC
Last Updated:9 days ago
View all publications at Europe PMC